For instance, RET inhibitors, including pralsetinib and selpercatinib (also referred to as LOXO-292), have been approved for the treatment of RET fusion-positive or mutant non-small cell lung cancer (Griesinger et al., 2022; Wright, 2020). This evidence concerns the gene RET and non-small cell lung carcinoma.